Accent Therapeutics secures funding to advance cancer therapies
2024-01-24
临床1期
Preview
来源: Pharmaceutical Technology
The Series C financing will support the advancement of innovative oncology drug candidates through early clinical trials. Credit: Aunt Spray/Shutterstock.com.
Accent Therapeutics has announced the successful completion of a $75m Series C financing round to progress the development of small molecule precision cancer therapies.
The round was spearheaded by Mirae Asset Capital Life Science and saw contributions from new investors including Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb and Johnson & Johnson Innovation.
Current investors AbbVie Ventures, Atlas Venture, the Column Group, Droia Ventures, EcoR1 Capital, GV, the Mark Foundation for Cancer ResearchCancer Research and Timefolio Capital were among others participating.
The funds will be used for early clinical development of Accent’s leading drug candidates.
These include a DExH-Box Helicase 9 (DHX9) inhibitor and a kinesin family member 18A (KIF18A) inhibitorkinesin family member 18A (KIF18A) inhibitor, with a focus on safety, pharmacokinetics and early efficacy studies.
Mirae Asset Capital Life Science managing director Naveen Krishnan will become part of Accent’s board of directors.
Accent’s lead candidate, a DHX9 inhibitor, is aimed at treating cancers with significant unmet medical needs, such as those associated with breast cancer gene (BRCA) loss of function (breast and ovarian cancers) and mismatch repair deficiency (colorectal, endometrial and gastric cancers).
The company’s second lead programme, a KIF18A inhibitorKIF18A inhibitor, has the potential to address a wide range of cancer indications with high unmet needs, including triple-negative breast cancer and ovarian cancer.
Accent Therapeutics CEO Shakti Narayan stated: “We are delighted to announce the backing of an exceptional investor syndicate [that shares] our commitment to advancing innovative therapies for patients with cancer.
“These additional resources position us well to file INDs [investigational new drug applications] this year for both our DHX9 and KIF18A programmes, and to rapidly progress them through early clinical development.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。